QSAM Biosciences recruits EFCC at MU SOM as upcoming trial site for CycloSam

QSAM Biosciences announces the addition of the Ellis Fischel Cancer Center, EFCC, at the University of Missouri, MU, School of Medicine, SOM, as an upcoming clinical trial site to soon begin enrolling participants into the Phase 1 study evaluating CycloSam for participants with multiple types of bone cancer that either originated in or has metastasized to the bone. QSAM‘s study is a multiple center, open label, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam in participants, and also assess early efficacy signals. Participants with bone cancer that has metastasized from the breast, lungs, prostate or other organs, as well as participants with cancer that has originated in the bone such as osteosarcoma and Ewing’s Sarcoma – diseases that mostly affect children and young adults — are also eligible subject to the trial’s inclusion and exclusion criteria. "We are pleased and excited to bring on the team at the Ellis Fischel Cancer Center with their experience and resources to continue to advance our clinical development program for CycloSam(R)," stated Douglas R. Baum, CEO. "We are looking forward to their active participation in completing this clinical trial in 2023 and working with us on the next phase of development later this year."